Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

14.3%

1 terminated/withdrawn out of 7 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A

5(83.3%)

Phase 4

1(16.7%)

6Total

N/A(5)

Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT05606146Not ApplicableUnknown

IUB SEAD RED (Revolutionary Endometrial Ablation Device Study)

Role: lead

NCT04959396Not ApplicableUnknown

IUB SEAD RED (Revolutionary Endometrial Ablation Device Study

Role: lead

NCT04381416Not ApplicableCompleted

Study to Assess the Safety and Efficacy of the IUB SEAD™ Device

Role: lead

NCT01590563Not ApplicableCompleted

A Study to Evaluate the Safety and Initial Efficacy of a Novel Intrauterine Device

Role: lead

NCT02778061Completed

IUB(TM) SCu300B - Post Marketing Performance Study in Austria

Role: lead

NCT02036177Phase 4Completed

Multivariate Assessment of the IUB Intrauterine Device Compared With a T380A IUD

Role: lead

NCT02036203Not ApplicableWithdrawn

A Study on the Safety and Efficacy of the SCu300A IUB Compared to the TCu380 Copper IUD

Role: lead

All 7 trials loaded